Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection

Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlafti, Eleni F., Hatzitolios, Apostolos I., Karlaftis, Anastasios F., Baltatzi, Maria S., Koliakos, Georgios G., Savopoulos, Christos G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831737/
https://www.ncbi.nlm.nih.gov/pubmed/24302832
http://dx.doi.org/10.4103/0975-7406.120067
Descripción
Sumario:Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.

Ejemplares similares